Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia by Alan H. Shih, Stephen S. Chung, Emily K. Dolezal, Su-Jiang Zhang, Omar I. Abdel-Wahab, Christopher Y. Park, Stephen D. Nimer, Ross L. Levine, Virginia M. Klimek

Get full text

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia by Catherine C. Coombs, David A. Sallman, Sean M. Devlin, Shweta Dixit, Abhinita Mohanty, Kristina Knapp, Najla H. Al Ali, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji, Eric Padron, Maria E. Arcila, Virginia M. Klimek, Marcel R. M. van den Brink, Martin S. Tallman, Ross L. Levine, Raajit K. Rampal, Franck Rapaport

Get full text

MSI2 is required for maintaining activated myelodysplastic syndrome stem cells by James Taggart, Tzu-Chieh Ho, Elianna Amin, Haiming Xu, Trevor S. Barlowe, Alexendar R. Perez, Benjamin H. Durham, Patrick Tivnan, Rachel Okabe, Arthur Chow, Ly Vu, Sun Mi Park, Camila Prieto, Christopher Famulare, Minal Patel, Christopher J. Lengner, Amit Verma, Gail Roboz, Monica Guzman, Virginia M. Klimek, Omar Abdel-Wahab, Christina Leslie, Stephen D. Nimer, Michael G. Kharas

Get full text

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia by Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo-Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee Ward, Jennifer A. Smith, Gary Acton, Hagop M. Kantarjian, Robert K. Stuart

Get full text